Minoxidil: Medicine Shadam | Health
National Health Intelligence Agency (Anvisa) Published a new recommendation to Brazilian Drug Shadha Manufacturers MinoxidilAfter the cases Hypertricosis in children There is a significant increase in Europe. Learn more below:
What is hypertricosis?
To the hypertricos, Known as “wolf syndrome”, This is a rare skin condition Causes excessive hair growth In different parts of the body, forehead, back and arms, There may be genetic or earned sourceIn the case of European infants after two months Use Do MinoxTidil.
See more
In April 2023, the Naware Pharmacovisance Center in Spain learned about a baby case, he began to get hair in the back, after two months of use of the Minoxidil ointment. The situation once again became important after the 11 children were earned Wolf syndrome This year.
What is the relationship of minoxidil with “wolf syndrome”?
Minoxidil is a drug Usually sells in the form of ointment and used for bald treatmentBy promoting the growth of hair and hair in the body. It is common after use suspension, which stops hair growth.
In children, hypertricosis can be obtained in medication such as genetic or minoxidil (dermatologic therapy/pediatric dermatitis).
What does Anvisa say about Minoxidil?
With the evolution of cases, the Anvisa has released a statement For those who have a record of drugs in Brazil and Parents of newborns have been warned of additional care . In the use of the body.
In a statement, the agency requested it Include the risk of hypertricosis in children After accidental topical exposure to Minoxidil:
“Health professionals should warn patients who use minoxidil (topical solution) to prevent children of Medicine Shadam. Hand washing after the product app to prevent accidental relationship. Patients and children who use minoxidil in topical solution are often contacted with children. ”
This is the first warning of Anvisa for the theme here in Brazil.
Oliberal.com Web Editor, under the supervision of Gabriel Borges, Journalism Intern, Taiin Cavalkante.
